DRRX: DURECT Corporation Market Cap to Revenue Ratio

DURECT Corporation (DRRX) management competently directs R&D, although the business relies on external investment. The market capitalization-to-revenue ratio demonstrates the current market valuation, where the value of 18.60 reflects the metric's balance. The promising Larsucidin could become the first treatment for alcoholic hepatitis, yet risks remain in the high-tech epigenetics niche that competitors may develop simpler treatment methods.

Price-to-Revenue Ratio: DURECT Corp (DRRX) for 07/04/2022 - 09/27/2025

Analytical breakdowns for DURECT Corporation (DRRX)

- share price and consensus valuation forecast:

Price Performance Chart durect.com|DRRX - Analyst Consensus Forecast

- market capitalization information:

Market Capitalization DURECT Corp.|DRRX - Real Price to Acquire Entire Company

- business book valuation details:

Book Value per Share DURECT|DRRX - Company Book Value|Market Value to Book Value durect.com|DRRX - Company Total Assets

- business debt structure and liquidity details:

- company profitability and valuation multiples indicators:

DRRX - Company Net Income|Expected Net Profit DURECT Corporation|DRRX - Price to Earnings Ratio|Future Price to Earnings Multiple durect.com|DRRX - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio DURECT Corp.|DRRX - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months DURECT|DRRX - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months durect.com|DRRX - Earnings growth in current year|Earnings growth forecast for next year DURECT Corporation

- total revenue and sales volume data:

DRRX - Company Sales|Company Projected Revenue Volume durect.com|DRRX - P/S Multiple|Market Cap to Expected Sales Ratio DURECT Corp.

Summary company analytics:DURECT Corp

To objectively evaluate an issuer, a fund manager must separate market noise from the actual value of assets. This ratio compares market capitalization to annual sales volume, measuring the degree of investor confidence in the business's commercial efficiency. By analyzing the price-to-sales valuation, one can identify pricing anomalies and hidden undervaluation. For DURECT Corporation (DRRX), this indicator reflects the capitalization potential of unique epigenetic patents prior to the commercial approval of the drugs.

Who DURECT Corporation competes with